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The cumulative incidence of chronic kidney dis-
ease (CKD) varies from 13%-60% in adult studies
[1-3] to as high as 62% in children [4]. CKD usually
becomes apparent 6-12 months after hematopoietic
cell transplant (HCT), although it has been described
as early as 2 months and as late as 10 years posttrans-
plant. There are 3 distinct clinical manifestations of re-
nal disease that can occur in the HCT patient:
thrombotic microangiopathy (TMA), typically hemo-
lytic uremic syndrome (HUS), and idiopathic CKD
and nephrotic syndrome.
RISK FACTORS FOR TMA AND HUS AFTER HCT
Although no clear relationships have been found to
date for the development of TMA after HCT, a num-
ber of risk factors have been examined. In earlier stud-
ies, where HUS was the primary diagnosis, risk factors
identified were total-body irradiation (TBI) [1,4-6]
and calcinuerin inhibitor use [1,7-12]. However, in
more recent studies of TMA, acute GVHD (aGVHD)
grades II-IV, older age, and transplant from an unre-
lated donor are the primary risk factors identified
[13,14]. Other investigators have identified sinusoidal
obstruction syndrome, matched unrelated donors or
haploidentical donors, and lymphoid malignancy as
significant predictors of TMA after HCT in addition
to the above risk factors [2,15-17]. However, in chil-
dren who develop HUS after HCT, the presumptive
risk factor in these studies has been TBI used as part
of the conditioning regimen. For example, Tarbell et
al [4] studied 44 children (aged 3-15 years) with ALL
or neuroblastoma (NB) who underwent HCT.
Twenty-nine of these patients were alive and in remis-
sion 3 months after HCT and were evaluated in the
study. Eleven patients developed increases in BUN
and creatinine, and 10 were anemic and thrombocyto-
penic with evidence of hemolysis on peripheral blood
smear; they also had elevated LDH levels. In every pa-84tient except one, the hemolytic process resolved, yet
the renal insufficiency persisted. The pathologic find-
ings of mesangiolysis with intraglomerular capillary
aneurysm formation in conjunction with the labora-
tory abnormalities support the diagnosis of HUS in
these children. In another small study, Antignac et al
[5] described 7 children referred to their nephrology
clinic with renal insufficiency approximately 5-10
months after TBI followed by HCT. All 7 children
had leukemia and all received cyclophosphamide
alone, or with cytosine arabinoside and vepeside, in ad-
dition to single-dose TBI as part of their conditioning
regimen. Three patients developed chronic renal
insufficiency without hypertension. Four of the 7
developed HUS with severe hypertension and micro-
angiopathic hemolytic anemia. Of these, 2 had nor-
malization of their renal function. Follow-up
biopsies, however, showed extensive scarring of the re-
nal parenchyma but almost complete resolution of the
mesangiolysis. The glomeruli were globally sclerotic,
ischemic, or demonstrated mesangial hypercellularity.
Thus, there was evidence of persistent and progressive
renal damage in these patients despite normalization of
serum creatinine and urinalysis. The occurrence of two
different clinical presentations but similar pathology in
these children further supports the notion that this is
a spectrum of disease rather than distinct pathophysi-
ologic processes.
IDIOPATHIC CKD
Idiopathic CKD in this patient population is usu-
ally defined as an elevated serum creatinine or an ab-
normal glomerular filtration rate (GFR) 6-12 months
after transplant. The incidence of idiopathic CKD in
children after HCT varies from 11%-41% [18-21].
In one recent study, the incidence of CKD (GFR
\70 mL/min/1.73 m2) changed over time, with 41%
of children having CKD at 1 year, 31% at 3 years,
and only 11% of patients had CKD 7 years after trans-
plant [21]. In approximately 19% of patients,
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ter HCT. Berg and Bolme [22] followed 44 children
with ALL, AML, and severe aplastic anemia (SAA)
and found a significant decrease in GFR 1-2 years after
HCT when compared to their baseline GFR (ALL and
AML groups) or to a healthy control group, despite se-
rum creatinines that remained within normal limits.
An initial decrease in GFR was followed by stabiliza-
tion up to 5 years posttransplant. Proximal tubular
dysfunction has also been described in 14%-45% of
pediatric patients 1-2 years after HCT [23]. In this
same study, GFR measured by inulin clearance, was
significantly lower than prior to transplant, but re-
mained within the normal range 2 years later.
RISK FACTORS FOR IDIOPATHIC CKD
The risk factors for idiopathic CKD in children are
similar to those identified in adult studies. Kist-van
Holthe et al [24] also retrospectively identified risk fac-
tors for the development of both acute and chronic re-
nal insufficiency in a cohort of 142 children
undergoing transplant over a period of 5 years in
The Netherlands [24]. All children received allogeneic
transplants. Ninety-one children received radiation,
and 82 of these 91 received TBI. Twenty-five children
(18%) had CKD (defined as a GFR\85 mL/min/1.73
m2). These authors found no correlation between radi-
ation dose used and renal insufficiency at 1 year. In
a later study from the same group, only acute renal in-
sufficiency predicted the later development of CKD in
patients after HCT [20]. These studies contradict
others in the literature that found TBI to be associated
with renal injury [18,19,25]. However, the doses used
here (5-8 Gy in a single fraction) were much lower
than described elsewhere.
In a study of 92 pediatric HCT patients by van
Why et al [18], late renal insufficiency developed in
18 of 64 (28%) patients; in half of these patients, the
renal disease persisted for 3 months to 3 years [18].
Amphotericin B use, cyclosporine, and TBI were
associated with the later development of CKD.
In a large retrospective review of 1635 children and
adults, risk factors for the development of CKD after
HCT included acute renal failure, aGVHD, and
chronic graft-versus-host disease (cGVHD) [2]. In
this study, TBI was not associated with development
of CKD.
NEPHROTIC SYNDROME AFTER HCT
Chronic GVHD may manifest itself in the kidney
as nephrotic syndrome with or without renal insuffi-
ciency (reviewed in [26]). Patients usually present
with proteinuria, edema, and hypoalbuminemia. The
majority of these case reports demonstrated membra-
nous nephropathy (MN) with subepithelial deposits
on biopsy; it is postulated that these deposits are anti-gen/antibodies complexes representing GVHD in the
kidney. However, cases of minimal change disease
(MCD), which is thought to be a T cell-mediated pro-
cess, have been described [26]. Comparisons between
case reports of membranous nephropathy and minimal
change disease after HCT found that membranous ne-
phropathy occurs in 61% of cases compared to 22% of
cases having MCD [27]. The majority of reported pa-
tients with membranous nephropathy were slightly
older males, and had a history of aGVHD and
cGVHD. Both MCD and MN occur later after trans-
plant at 8 and 14 months, respectively, and tend to oc-
cur within 1-5 months of the development of GVHD
and/or the tapering of immunosuppression for their
cGVHD. Membranous nephropathy is more difficult
to treat with only 27% of patients reported achieving
remission compared to 90% of patients with MCD
[27]. Others have reported cases of diffuse proliferative
glomerulonephritis, ANCA-related glomerulonephri-
tis, focal segmental glomerulosclerosis, and IgA ne-
phropathy [28-32] occurring after HCT. The
development of each of these diseases seems to be asso-
ciated with cGVHD and/or the tapering of immuno-
suppression. Treatment with high-dose prednisone
and/or reinstitution of calcinuerin inhibitors usually
results in resolution of nephrotic syndrome. Some
physicians have used rituximab successfully in patients
with nephrotic syndrome after HCT, typically in cases
of membranous nephropathy [33].
MANAGEMENT OF CKD AFTER HCT
Patients who develop CKD after hematopoietic
stem cell transplants are at increased risk of mortality
[34]. Based on animal models of HCT and specifically
of radiation-induced HUS, there are potential inter-
ventions for patients with HUS after HCT. Angioten-
sin-converting enzyme inhibitors (ACEI) have been
used in rodent models of HCT-related renal injury.
The use of captopril or enalapril at the time of TBI
in these animals resulted in less azotemia, lower blood
pressures, and long-term preservation of renal func-
tion [35]. ACEI and antiotensin receptor blockers
(ARBs) also help to reduce inflammation and inflam-
matory markers in patients after transplant [36,37].
These agents have also been shown to slow progres-
sion of CKD in patients with renal disease from vari-
ous causes [38,39]. However, these mouse models
were of radiation induced injury and because it is likely
that TBI is not playing a role in idiopathic CKD, it
may be that the potential beneficial effects of ACEI
and ARBs in these patients are their potential to reduce
blood pressure as well as inflammation and inflamma-
tory markers in patients. Randomized controlled trials
using ACEI or ARB have not yet been published in
people undergoing HCT, although a trial is currently
underway.
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plant may include the use of peritoneal and/or hemo-
dialysis. Caring for these patients also involves
management of the complications associated with
ESRD which include anemia, bone disease, hyperten-
sion, and metabolic abnormalities. There have been
case series of patients undergoing renal transplantation
successfully after HCT, and it is a viable option for pa-
tients with end-stage renal disease after HCT [40-42].
In patients who received their kidney from the same
donor as their stem cells, little or no immunosuppres-
sion is required.
SUMMARY
There are 3 clearly distinct clinical entities that oc-
cur after HCT: TMA, idiopathic CKD, and nephrotic
syndrome. The potentially independent role of
GVHD and chronic inflammation in the development
and progression of idiopathic CKD warrants further
investigation. CKD after HCT is a relatively common
occurrence. As the indications for and number of
transplants performed world wide increases, so will
the burden of kidney disease. Identifying those pa-
tients at risk for the development of CKD will be im-
portant for potential intervention and prevention of
CKD and progression to end-stage renal disease in
this patient population. There are those patients who
will develop CKD that is not related to TBI or the con-
ditioning regimen but rather to complications and/or
therapy that occur after HCT, specifically aGVHD
and cGVHD and prolonged calcinuerin inhibitor
use. The burden of management will fall not only to
the nephrologists but the oncologist as well to ensure
close monitoring of renal function, blood pressure,
and urinalyses posttransplant. It may be that our ener-
gies have been misdirected in trying to reduce expo-
sure to TBI, and rather we should try to decrease the
inflammatory and cytokine effects of GVHD and re-
duce exposure to calcineurin inhibitors to prevent
CKD in this population of patients.
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